ReviewBiomarkers in medicine2014
Biomarkers in psychosis: an approach to early identification and individualized treatment.
Review in Biomarkers in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Interindividual Sleep Variability Across the Psychosis Spectrum: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- On the proportion of patients who experience a prodrome prior to psychosis onset: A systematic review and meta-analysis.Molecular psychiatry · 2024Pooled it
- Macro- and Microstructural Alterations in the Midbrain in Early Psychosis Associates with Clinical Symptom Scores.eNeuro · 2025Article
- Illness Phase as a Key Assessment and Intervention Window for Psychosis.Biological psychiatry global open science · 2023Review
- Identification of Diagnostic Schizophrenia Biomarkers Based on the Assessment of Immune and Systemic Inflammation Parameters Using Machine Learning Modeling.Sovremennye tekhnologii v meditsine · 2023Article
- Machine Learning and Non-Affective Psychosis: Identification, Differential Diagnosis, and Treatment.Current psychiatry reports · 2022Review
- Subtyping Schizophrenia Patients Based on Patterns of Structural Brain Alterations.Schizophrenia bulletin · 2022Article
- Current challenges and possible future developments in personalized psychiatry with an emphasis on psychotic disorders.Heliyon · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Numerous biomarkers for somatic disorders are used in routine medical practice. Yet, despite remarkable advances in mental health research, we are not able to identify biomarkers with established clinical utility for mental disorders such as schizophrenia. While identification and characterization of biomarkers are crucial first steps in this process, their predictive diagnostic and treatment utility need to be better developed for clinical practice. The heterogeneity of psychotic disorders etiologically, pathologically and symptomatically presents both a challenge and an opportunity for the use of biomarkers in clinical practice. Simply said, a single biomarker might not exist that necessitates the search for a biomarker profile. In this review we discuss research findings in light of such an approach. We summarize some examples of emerging biomarkers in early psychosis research and delineate how these can be applied to a clinical setting to inform treatment on an individual basis fostering a personalized treatment approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.